Lyme Disease - Drug Pipeline Landscape, 2023

Lyme Disease - Drug Pipeline Landscape, 2023

Lyme disease is a tick-borne infection caused by four main species of bacteria Borrelia burgdorferi, Borrelia mayonii, Borrelia afzelii and Borrelia garinii. The disease is characterized by skin rash.

Early signs and symptoms of Lyme disease include rash and other symptoms like fever, chills, fatigue, body aches, and swollen lymph nodes. Later symptoms include erythema migrans, joint pain and other neurological problems.

Diagnosis of Lyme disease involves lab tests to identify antibodies to the bacteria can help confirm or rule out the diagnosis. They include ELISA test, Western blot test and polymerase chain reaction test.

Lyme disease is treated by using oral antibiotics and intravenous antibiotics. Doxycycline, amoxicillin, or cefuroxime antibiotics are used for treatment.

The companies active in the development of Lyme Disease Drugs include Valneva, Tarsus Pharmaceuticals, Cortene etc.

Clinical trials are ongoing for several drugs in development for Lyme disease. These drugs are in various stages of development, from early preclinical stages to late-stage clinical trials.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Lyme Disease treatment such as VLA15, 2217LS, CT38 and others. Key players involved in the development of therapies to treat Lyme Disease are Abzyme Therapeutics, Blue Lake Biotechnology, Cortene Inc, MassBiologic, Valneva Austria GmbH and others. One drug is under late-stage Phase III clinical trials and three drugs are in Phase I clinical trials and some other drugs are under preclinical and discovery stages of development.

In December 2022, Valneva announced that lyme disease vaccine edging closer with Valneva and Pfizer data.

Report Highlights

Global Insight Service's, Lyme Disease - Drug Pipeline Landscape, 2023 report provides an overview of the Lyme disease pipeline drugs. This report covers detailed insights on Lyme Disease drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Lyme Disease pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.